Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Follicular Lymphoma
Related studies linked through entity extraction aliases.
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
- Status
- COMPLETED
- Phase
- PHASE3
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
- Status
- COMPLETED
- Phase
- PHASE1
BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Status
- TERMINATED
- Phase
- NA
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Status
- RECRUITING
- Phase
- PHASE3